| Outcome Measures: |
Primary: HbA1c change from baseline at week 24, Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24, Baseline and week 24 | Secondary: The Safety of HSK7653 at Week 24 and Week 52, Incidence of Treatment-Emergent Adverse Events over time (at week 24 and week 52), Baseline, week 24 and week 52|Percentage of Patients With HbA1c <7.0%, Baseline, week 24 and week 52|Percentage of Patients With HbA1c <6.5%, Baseline, week 24 and week 52|FPG Change From Baseline at Week 24 and Week 52, Baseline, week 24 and week 52|2h-PPG Change From Baseline at Week 24 and Week 52, Baseline, week 24 and week 52|Weight Change From Baseline at Week 24 and Week 52, Baseline, week 24 and week 52|Fasting C-peptide Change From Baseline at Week 24 and Week 52, Baseline, week 24 and week 52|Insulin Sensitivity Change (Calculated by HOMA-IS) From Baseline at Week 24 and Week 52, Baseline, week 24 and week 52|Pancreatic β-cell function Change (Calculated by HOMA-β ) From Baseline at Week 24 and Week 52, Baseline, week 24 and week 52|Percentage of Patients Required Use of Rescue Therapy or Dropout due to Hyperglycemia, Baseline, week 24 and week 52
|
| Locations: |
Peking University People's Hospital, Beijing, Beijing, 100044, China|Zhujiang Hospital of Southern Medical University, Zhujiang, Guangdong, China
|
